These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 31776206)

  • 1. Tumor Microenvironment following Gemcitabine Treatment Favors Differentiation of Immunosuppressive Ly6C
    Wu C; Tan X; Hu X; Zhou M; Yan J; Ding C
    J Immunol; 2020 Jan; 204(1):212-223. PubMed ID: 31776206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer.
    Kajiwara Y; Tazawa H; Yamada M; Kanaya N; Fushimi T; Kikuchi S; Kuroda S; Ohara T; Noma K; Yoshida R; Umeda Y; Urata Y; Kagawa S; Fujiwara T
    Cancer Immunol Immunother; 2023 May; 72(5):1285-1300. PubMed ID: 36436021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy-Derived Inflammatory Responses Accelerate the Formation of Immunosuppressive Myeloid Cells in the Tissue Microenvironment of Human Pancreatic Cancer.
    Takeuchi S; Baghdadi M; Tsuchikawa T; Wada H; Nakamura T; Abe H; Nakanishi S; Usui Y; Higuchi K; Takahashi M; Inoko K; Sato S; Takano H; Shichinohe T; Seino K; Hirano S
    Cancer Res; 2015 Jul; 75(13):2629-40. PubMed ID: 25952647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct chemotherapy-associated anti-cancer immunity by myeloid cells inhibition in murine pancreatic cancer models.
    Sakai Y; Miyazawa M; Komura T; Yamada T; Nasti A; Yoshida K; Takabatake H; Yamato M; Yamashita T; Yamashita T; Mizukoshi E; Okuzono M; Ho TTB; Kawaguchi K; Wada T; Honda M; Kaneko S
    Cancer Sci; 2019 Mar; 110(3):903-912. PubMed ID: 30657234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ganoderma lucidum spores-derived particulate β-glucan treatment improves antitumor response by regulating myeloid-derived suppressor cells in triple-negative breast cancer.
    Bu Y; Liu Q; Shang Y; Zhao Z; Sun H; Chen F; Ma Q; Song J; Cui L; Sun E; Luo Y; Shu L; Jing H; Tan X
    Int J Biol Macromol; 2024 Jun; 270(Pt 1):131949. PubMed ID: 38749890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine nanoparticles promote antitumor immunity against melanoma.
    Zhang Y; Bush X; Yan B; Chen JA
    Biomaterials; 2019 Jan; 189():48-59. PubMed ID: 30388589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined blockade of TGf-β1 and GM-CSF improves chemotherapeutic effects for pancreatic cancer by modulating tumor microenvironment.
    Liu Q; Wu H; Li Y; Zhang R; Kleeff J; Zhang X; Cui M; Liu J; Li T; Gao J; Pan B; Wu W; Wang W; Zhou L; Guo J; Dai M; Zhang T; Liao Q; Lu Z; Zhao Y
    Cancer Immunol Immunother; 2020 Aug; 69(8):1477-1492. PubMed ID: 32285172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of
    Phan T; Nguyen VH; Buettner R; Morales C; Yang L; Wong P; Tsai W; Salazar MD; Gil Z; Diamond DJ; Rabinowitz JD; Rosen S; Melstrom LG
    Int J Biol Sci; 2021; 17(9):2240-2251. PubMed ID: 34239352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of antitumor immunity in lung cancer by targeting myeloid-derived suppressor cell pathways.
    Sawant A; Schafer CC; Jin TH; Zmijewski J; Tse HM; Roth J; Sun Z; Siegal GP; Thannickal VJ; Grant SC; Ponnazhagan S; Deshane JS
    Cancer Res; 2013 Nov; 73(22):6609-20. PubMed ID: 24085788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual depletion of myeloid-derived suppressor cells and tumor cells with self-assembled gemcitabine-celecoxib nano-twin drug for cancer chemoimmunotherapy.
    Zhang X; Liang Q; Cao Y; Yang T; An M; Liu Z; Yang J; Liu Y
    J Nanobiotechnology; 2024 Jun; 22(1):319. PubMed ID: 38849938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts.
    Waters JA; Matos J; Yip-Schneider M; Aguilar-Saavedra JR; Crean CD; Beane JD; Dumas RP; Suvannasankha A; Schmidt CM
    Surgery; 2015 Oct; 158(4):881-8; discussion 888-9. PubMed ID: 26209568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model.
    Meyer C; Sevko A; Ramacher M; Bazhin AV; Falk CS; Osen W; Borrello I; Kato M; Schadendorf D; Baniyash M; Umansky V
    Proc Natl Acad Sci U S A; 2011 Oct; 108(41):17111-6. PubMed ID: 21969559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclophosphamide-induced myeloid-derived suppressor cell population is immunosuppressive but not identical to myeloid-derived suppressor cells induced by growing TC-1 tumors.
    Mikyšková R; Indrová M; Polláková V; Bieblová J; Símová J; Reiniš M
    J Immunother; 2012 Jun; 35(5):374-84. PubMed ID: 22576342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice.
    Zoglmeier C; Bauer H; Noerenberg D; Wedekind G; Bittner P; Sandholzer N; Rapp M; Anz D; Endres S; Bourquin C
    Clin Cancer Res; 2011 Apr; 17(7):1765-75. PubMed ID: 21233400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity.
    Suzuki E; Kapoor V; Jassar AS; Kaiser LR; Albelda SM
    Clin Cancer Res; 2005 Sep; 11(18):6713-21. PubMed ID: 16166452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
    Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
    Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor effects of anti-CD40/CpG immunotherapy combined with gemcitabine or 5-fluorouracil chemotherapy in the B16 melanoma model.
    Qu X; Felder MA; Perez Horta Z; Sondel PM; Rakhmilevich AL
    Int Immunopharmacol; 2013 Dec; 17(4):1141-7. PubMed ID: 24201083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine treatment promotes immunosuppressive microenvironment in pancreatic tumors by supporting the infiltration, growth, and polarization of macrophages.
    Deshmukh SK; Tyagi N; Khan MA; Srivastava SK; Al-Ghadhban A; Dugger K; Carter JE; Singh S; Singh AP
    Sci Rep; 2018 Aug; 8(1):12000. PubMed ID: 30097594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer.
    Annels NE; Shaw VE; Gabitass RF; Billingham L; Corrie P; Eatock M; Valle J; Smith D; Wadsley J; Cunningham D; Pandha H; Neoptolemos JP; Middleton G
    Cancer Immunol Immunother; 2014 Feb; 63(2):175-83. PubMed ID: 24292263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T-cell activation events.
    Schouppe E; Mommer C; Movahedi K; Laoui D; Morias Y; Gysemans C; Luyckx A; De Baetselier P; Van Ginderachter JA
    Eur J Immunol; 2013 Nov; 43(11):2930-42. PubMed ID: 23878002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.